News
NEWCASTLE, UK I April 25, 2025 I Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters ...
Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback